Q-omics provides the consensus-scored ST6GAL1 profile across patient tissues and cancer cell-line models. ST6GAL1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ST6GAL1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ST6GAL1 protein abundance shows 19,987 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ST6GAL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST6GAL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST6GAL1 survival associations across molecular data types. ST6GAL1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST6GAL1 RNA expression–survival associations across cancer types. High ST6GAL1 expression shows unfavorable associations in ACC, but favorable associations in HNSC, LUAD, MESO, LIHC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ST6GAL1 RNA expression.
This table summarizes ST6GAL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ST6GAL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST6GAL1 shows lower tumor expression in KIRC, KICH, KIRP, THCA and LUSC and higher tumor expression in STAD. The KIRC box plot shows higher ST6GAL1 RNA expression in normal versus tumor tissue (log2 FC = −2.756, t-test p < 0.001).
This table shows molecular features associated with ST6GAL1 in patient tissues and cancer cell lines. In patient samples, ST6GAL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ST6GAL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
